8-K current report · filed Jul 29, 2026

Anika Therapeutics, Inc. (ANIK) 8-K Current Report: July 29, 2026

Item 2.02Item EX-99.1ANIK overview

Short answer

Anika Therapeutics, Inc. (ANIK) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.

Anika Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026
  • Press release furnished as Exhibit 99.1 contains financial results
  • Disclosure furnished under Item 2.02, generally outside Section 18 liability

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $32.6M, up 16%, with Commercial Channel revenue up 17% to record $13.9M
  • Gross margin expanded to 65%, driving $3.3M GAAP net income and $7.1M adjusted EBITDA
  • Full-year 2026 guidance raised: revenue growth 5%-10%, adjusted EBITDA margin 13%-17%
  • Cash fell to $38.4M from $57.5M at December 31, 2025, including $9.5M of share repurchases and $5.5M operating cash use
  • 2027 Commercial Channel growth outlook reduced to 5%-15% from 10%-20%, excluding unapproved Hyalofast revenue due to FDA timing uncertainty

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Anika Therapeutics, Inc. 8-K filings

Get the next ANIK 8-K as it lands

Follow ANIK for push alerts, or ask the research agent what this filing means.